Development and Internal Validation of a Diagnostic Nomogram for Identifying Left Atrial Enlargement in Patients with Essential Hypertension Authors: Wei Wen, Yanyu Huang, Jiahuan Rao, Haibo Chen Published: 2026 ABSTRACT ObjectiveLeft atrial enlargement (LAE) is a critical indicator of target organ damage in essential hypertension. However, simple and accessible tools for individualized early screening in routine practice remain limited. This study derived and internally validated a practical nomogram using standard clinical metrics to estimate LAE probability, acknowledging its development within a single retrospective cross-sectional study.MethodsClinical data from 251 hypertensive patients admitted to our hospital between August 2023 and September 2024 were retrospectively reviewed. Because clinical predictors and echocardiographic LAE were assessed concurrently, a retrospective cross‑sectional design was applied. LAE was defined according to guideline‑based left atrial anteroposterior diameter criteria. Five clinically prespecified candidate variables (age, hypertension duration, atrial fibrillation, hypertension stage, and coronary heart disease) were entered into a multivariable logistic regression model to construct the nomogram. Discriminative performance was quantified by the area under the receiver operating characteristic (ROC) curve (AUC).ResultsThe final model included all five variables. Older age (p < 0.001), increased hypertension duration (p = 0.010), and atrial fibrillation (AF) were independently associated with the presence of LAE. Hypertension stage and coronary heart disease (CHD), though not statistically independent, were retained for clinical relevance. The derived nomogram showed high internal discrimination, with an AUC of 0.937.ConclusionIn the final model, older age (per year increase: OR = 1.15, 95% CI: 1.08–1.24, p < 0.001), increased hypertension duration (per grade increase: OR = 2.00, 95% CI: 1.25–3.57, p = 0.003), AF (OR = 3.70, 95% CI: 1.15–12.12, p = 0.028), and CHD were identified as independent predictors. Hypertension stage did not reach statistical significance (stage 2: OR = 0.78, 95% CI: 0.17–3.85, p = 0.753; stage 3: OR = 1.96, 95% CI: 0.50–9.22, p = 0.340) but was deliberately retained in the final model owing to its established clinical relevance and pathophysiological role in hypertensive atrial remodeling. The tool demonstrated high internal discrimination, with an apparent AUC of 0.937 and an optimism‑corrected AUC of 0.920 after 1000 bootstrap resamples, along with high calibration accuracy (mean absolute error: 0.017). Introduction Essential hypertension, a major cardiovascular risk factor, contributes to progressive target-organ damage and imposes a substantial global public health burden.1–3 Because these early pathological modifications are largely asymptomatic during their initial stages, they are frequently overlooked by patients, which delays timely clinical intervention. Among recognized forms of hypertension-mediated organ damage (HMOD), left atrial enlargement (LAE) has emerged as an early manifestation of hypertensive heart disease.4,5 Chronically elevated systemic afterload impairs left ventricular relaxation and raises end-diastolic filling pressures. This mechanical burden is transmitted retrogradely, obligating structural remodeling and subsequent dilation of the atrial chamber.6 Importantly, structural dilation represents only the macroscopic manifestation of a more complex pathological entity; the concept of atrial cardiomyopathy has recently emerged to describe these subclinical electrical, structural, and mechanical alterations of the atria, which carry significant prognostic implications independent of ventricular function.7 LAE represents a clinically relevant marker of pathological cardiovascular remodeling rather than a benign physiological adaptation in patients with cardiovascular risk factors. The extent of atrial chamber expansion correlates strongly with incident atrial fibrillation (AF), ischemic stroke, heart failure, and overall cardiovascular mortality.8,9 Early detection of this structural remodeling directly informs patient risk stratification and guides clinical management. Echocardiography remains the clinical reference for evaluating atrial geometry. Contemporary guidelines increasingly emphasize the left atrial volume index (LAVI) as the preferred, more accurate parameter for evaluating three-dimensional left atrial remodeling compared with simple linear measurements. However, left atrial anteroposterior diameter remains widely used in primary care and historical electronic records owing to its high reproducibility and technical simplicity. The widespread utility of comprehensive echocardiography in primary care is often constrained by operator expertise, costs, and equipment access. This necessity underscores the need for accessible, non-invasive screening tools based on routine clinical variables to optimize individualized cardiovascular preventive strategies.10 The development of a nomogram provides a statistical framework for risk quantification, aligning with standardized reporting guidelines for predictive modeling.11 To address current diagnostic limitations, this study aimed to identify clinically relevant factors associated with LAE and to develop a diagnostic nomogram that estimates the probability of concurrent LAE in patients with essential hypertension. The model may offer a simple approach for individualized risk stratification and facilitate targeted echocardiographic assessment. Methods Study Population This retrospective, single-center, cross-sectional study enrolled patients with a diagnosis of essential hypertension who were admitted to the Department of Cardiology at our hospital between August 2023 and September 2024. Because clinical candidate predictors and echocardiographic parameters were evaluated concurrently during the index hospitalization, a cross-sectional design was adopted. All data were extracted from routine clinical medical records; no intervention or additional procedures were performed on patients, and all patient information was de-identified. The study was conducted in accordance with the ethical requirements for retrospective analysis of routine clinical data and with the Declaration of Helsinki.12 Hypertension was diagnosed based on clinical guidelines.13 Inclusion criteria were: (1) age ≥ 18 years; (2) confirmed diagnosis of essential hypertension; and (3) availability of complete baseline clinical and echocardiographic data obtained during the same hospital admission. Exclusion criteria were: (1) secondary hypertension; (2) severe valvular heart disease, congenital heart disease, or cardiomyopathies; (3) severe hepatic or renal dysfunction; and (4) acute myocardial infarction or active systemic infection. Data Collection and Definitions Baseline clinical data, including age, hypertension duration, and history of AF, were retrieved from the electronic medical record system. The duration of hypertension was categorized into five ordinal grades: grade 1 (<1 year), grade 2 (1–5 years), grade 3 (5–10 years), grade 4 (10–20 years), and grade 5 (≥20 years). Transthoracic echocardiography was performed by experienced sonographers. Left ventricular hypertrophy (LVH) was defined according to the echocardiographic diagnosis documented in the medical records. LVH was assessed based on routine echocardiographic evaluation and was not determined by electrocardiography or physical examination. The study outcome was the presence of LAE, defined as a left atrial anteroposterior diameter >40 mm in men and >38 mm in women, according to the American Society of Echocardiography (ASE) recommendations.14 Although LAVI is currently recommended as a preferred volumetric parameter for assessing left atrial size, LAVI measurements were not consistently available in our historical echocardiographic records due to the retrospective design. Therefore, left atrial anteroposterior diameter was used as the available echocardiographic indicator of LA enlargement. Statistical Analysis Continuous variables were presented as mean ± standard deviation, while categorical data were presented as frequencies and proportions. Given the limited number of outcome events (26 LAE cases), a prespecified strategy was applied; five clinically relevant candidate variables (age, hypertension duration, history of AF, hypertension stage, and coronary heart disease [CHD]) were selected a priori and entered into the multivariable logistic regression model without algorithmic feature selection. No data-driven variable selection procedure was applied because of the limited number of LAE events and the potential risk of model instability and overfitting associated with such approaches. For clinically intuitive interpretation and statistical objectivity, odds ratios (ORs) for continuous and ordinal variables were reported according to their original scales. Although hypertension stage and coronary heart disease (CHD) were not statistically significant as an individual predictor in the multivariable model, they were retained a priori in the final model owing to their established clinical relevance and pathophysiological plausibility in hypertensive structural atrial remodeling, as strict reliance on an arbitrary p < 0.05 threshold might omit clinically important predictors and reduce clinical interpretability. All odds ratios (OR) and 95% confidence intervals (CI) were derived from the multivariable logistic regression model. Based on the multivariable findings, a diagnostic nomogram was developed with the rms package in R. Discriminatory power was assessed by the area under the receiver operating characteristic (ROC) curve (AUC). To evaluate model stability and adjust for overfitting, internal validation was performed using bootstrapping with 1,000 resamples to calculate an optimism-corrected AUC. Calibration was assessed using calibration curves with mean absolute error (MAE), the Hosmer-Lemeshow goodness-of-fit test, and the Brier score. All tests were two-tailed, with P < 0.05 considered statistically significant (except for the clinically retained predictor as specified). All analyses and model reporting followed the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) guidelines.11 Results Baseline Characteristics A total of 251 patients were included in this study (selection workflow illustrated in Figure 1). Table 1 summarizes the baseline clinical characteristics of the study population, stratified by LAE status. Compared with the non-LAE group, the LAE group had significantly older age, longer hypertension duration, and higher AF prevalence. Sex distribution did not differ significantly between the two groups (p = 0.086).Table 1Baseline Clinical and Echocardiographic Characteristics of the Study Population Categorized by the Presence of Left Atrial EnlargementCharacteristicsNon-LAE (n = 225)LAE (n = 26)pAge, years63.00 [54.00, 69.00]79.00 [71.50, 83.00]< 0.001Sex, n (%)0.086 Male114 (50.7%)8 (30.8%) Female111 (49.3%)18 (69.2%)Hypertension stage, n (%)0.101 Stage 173 (32.4)4 (15.4) Stage 281 (36.0)9 (34.6) Stage 371 (31.6)13 (50.0)Hypertension duration, median (IQR)2.00 [2.00, 4.00]5.00 [4.00, 5.00]<0.001AF, n (%)< 0.001 No208 (92.4)13 (50.0) Yes17 (7.6)13 (50.0)CHD, n (%)0.023 No135 (60.0)9 (34.6) Yes90 (40.0)17 (65.4)LVH No179 (79.6)17 (65.4)0.16 Yes46 (20.4)9 (34.6)DD No21 (9.3)0 (0.0)0.21 Yes204 (90.7)26 (100.0)Notes: Data are presented as median [IQR] for continuous variables and n (%) for categorical variables. Figure 1Flowchart of the study population selection process.A flowchart of patient selection for a hypertension study, showing enrollment, exclusion and analysis steps. Table 1Baseline Clinical and Echocardiographic Characteristics of the Study Population Categorized by the Presence of Left Atrial EnlargementCharacteristicsNon-LAE (n = 225)LAE (n = 26)pAge, years63.00 [54.00, 69.00]79.00 [71.50, 83.00]< 0.001Sex, n (%)0.086 Male114 (50.7%)8 (30.8%) Female111 (49.3%)18 (69.2%)Hypertension stage, n (%)0.101 Stage 173 (32.4)4 (15.4) Stage 281 (36.0)9 (34.6) Stage 371 (31.6)13 (50.0)Hypertension duration, median (IQR)2.00 [2.00, 4.00]5.00 [4.00, 5.00]<0.001AF, n (%)< 0.001 No208 (92.4)13 (50.0) Yes17 (7.6)13 (50.0)CHD, n (%)0.023 No135 (60.0)9 (34.6) Yes90 (40.0)17 (65.4)LVH No179 (79.6)17 (65.4)0.16 Yes46 (20.4)9 (34.6)DD No21 (9.3)0 (0.0)0.21 Yes204 (90.7)26 (100.0)Notes: Data are presented as median [IQR] for continuous variables and n (%) for categorical variables. Baseline Clinical and Echocardiographic Characteristics of the Study Population Categorized by the Presence of Left Atrial Enlargement Notes: Data are presented as median [IQR] for continuous variables and n (%) for categorical variables. Flowchart of the study population selection process. Multivariable Logistic Regression Analysis A multivariable logistic regression analysis was performed using the prespecified clinical predictors (age, hypertension duration, AF, hypertension stage, and coronary heart disease) to construct a clinically applicable predictive model for LAE. Advanced age (per year increase: OR = 1.15, 95% CI: 1.08–1.24) and increased hypertension duration (per grade increase: OR = 2.00, 95% CI: 1.25–3.57) were independently associated with the presence of LAE. AF was also independently associated with LAE (OR = 3.7, 95% CI: 1.15–12.12). Hypertension stage and CHD did not reach statistical significance in the multivariable analysis but were retained in the final model because of their clinical relevance (Table 2).Table 2Multivariable Firth Logistic Regression Analysis of Factors Associated with LAEVariableOdds ratio95% Confidence IntervalP valueAge (per year increase)1.151.08–1.24<0.001aHypertension duration (per grade increase)2.001.25–3.570.003bHypertension stage Stage 11.00— Stage 20.780.17–3.850.753 Stage 31.960.50–9.220.340AF3.701.15–12.120.028CHD1.310.45–4.010.626Notes: a Hypertension duration was analyzed as an ordinal variable categorized into 5 grades based on time since diagnosis (Grade 1 to 5). The OR is reported per interquartile range (IQR = 2 units) increase. b Hypertension stage (HTN_ stage) was analyzed as a categorical variable (Stage 1, Stage 2, and Stage 3).Abbreviations: OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; HTN_stage, hypertension stage. Table 2Multivariable Firth Logistic Regression Analysis of Factors Associated with LAEVariableOdds ratio95% Confidence IntervalP valueAge (per year increase)1.151.08–1.24<0.001aHypertension duration (per grade increase)2.001.25–3.570.003bHypertension stage Stage 11.00— Stage 20.780.17–3.850.753 Stage 31.960.50–9.220.340AF3.701.15–12.120.028CHD1.310.45–4.010.626Notes: a Hypertension duration was analyzed as an ordinal variable categorized into 5 grades based on time since diagnosis (Grade 1 to 5). The OR is reported per interquartile range (IQR = 2 units) increase. b Hypertension stage (HTN_ stage) was analyzed as a categorical variable (Stage 1, Stage 2, and Stage 3).Abbreviations: OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; HTN_stage, hypertension stage. Multivariable Firth Logistic Regression Analysis of Factors Associated with LAE Notes: a Hypertension duration was analyzed as an ordinal variable categorized into 5 grades based on time since diagnosis (Grade 1 to 5). The OR is reported per interquartile range (IQR = 2 units) increase. b Hypertension stage (HTN_ stage) was analyzed as a categorical variable (Stage 1, Stage 2, and Stage 3). Abbreviations: OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; HTN_stage, hypertension stage. Nomogram Construction and Validation Using the five identified variables (age, hypertension duration, AF, hypertension stage, and coronary heart disease), a diagnostic nomogram for individualized risk assessment was formulated (Figure 2). The model showed good internal discrimination for LAE, with an apparent AUC of 0.937 on receiver operating characteristic (ROC) analysis (Figure 3). After internal validation using bootstrap resampling with 1,000 repetitions, the optimism-corrected AUC was 0.920, indicating relatively stable discriminative performance. Figure 2Nomogram for estimating the probability of concomitant LAE in patients with essential hypertension. To use the nomogram, locate the patient’s specific value on each individual variable axis (age, hypertension duration, atrial fibrillation, hypertension stage, and CHD). Draw a vertical line upward to the “Points” axis to determine the risk points assigned to that variable. Sum the points from all five variables and locate this total sum on the “Total Points” axis. Finally, draw a vertical line downward to the “Risk of LAE” axis to obtain the individual’s estimated probability of the presence of LAE. HTN_duration, hypertension duration was categorized into 5 grades: 1 (<1 year), 2 (1–5 years), 3 (5–10 years), 4 (10–20 years), and 5 (≥20 years).Nomogram for estimating LAE risk in essential hypertension patients: For each variable, select a value, align to the Points scale to read points, sum to Total Points, then read Risk of LAE. Points scale: 0 to 100. Age: 30-95. HTN duration (Grade): 1 to 5. Atrial Fibrillation: 0 or 1. Hypertension Stage: 1 to 3. Coronary Heart Disease: 0 or 1. Total Points: 0-160. Risk of LAE: 0.01, 0.05, 0.1, 0.2, 0.3, 0.5, 0.7, 0.8, 0.9, 0.95.A nomogram mapping age and hypertension variables to total points and risk of LAE.Abbreviations: LAE, left atrial enlargement; AF, atrial fibrillation. Figure 3Receiver operating characteristic (ROC) curve of the 5-variable clinical model for identifying LAE. The solid line represents the ROC curve of the final model incorporating age, hypertension duration, atrial fibrillation, hypertension stage, and coronary heart disease. The shaded area indicates the 95% confidence interval (CI) of the ROC curve. The diagonal line represents the reference line of no discrimination (AUC = 0.50). The apparent AUC was 0.937 (95% CI: 0.899–0.975); after internal validation with 1,000 bootstrap resamples, the optimism-corrected AUC was 0.920.A receiver operating characteristic curve showing sensitivity versus 1 minus specificity with a steep early rise. Nomogram for estimating the probability of concomitant LAE in patients with essential hypertension. To use the nomogram, locate the patient’s specific value on each individual variable axis (age, hypertension duration, atrial fibrillation, hypertension stage, and CHD). Draw a vertical line upward to the “Points” axis to determine the risk points assigned to that variable. Sum the points from all five variables and locate this total sum on the “Total Points” axis. Finally, draw a vertical line downward to the “Risk of LAE” axis to obtain the individual’s estimated probability of the presence of LAE. HTN_duration, hypertension duration was categorized into 5 grades: 1 (<1 year), 2 (1–5 years), 3 (5–10 years), 4 (10–20 years), and 5 (≥20 years). Receiver operating characteristic (ROC) curve of the 5-variable clinical model for identifying LAE. The solid line represents the ROC curve of the final model incorporating age, hypertension duration, atrial fibrillation, hypertension stage, and coronary heart disease. The shaded area indicates the 95% confidence interval (CI) of the ROC curve. The diagonal line represents the reference line of no discrimination (AUC = 0.50). The apparent AUC was 0.937 (95% CI: 0.899–0.975); after internal validation with 1,000 bootstrap resamples, the optimism-corrected AUC was 0.920. Calibration was further assessed. Internal validation via 1,000 bootstrap resamples revealed good calibration performance, with a mean absolute error (MAE) of 0.017, demonstrating close agreement between nomogram‑predicted probabilities and observed outcomes (Figure 4). The Hosmer‑Lemeshow goodness‑of‑fit test yielded a non‑significant result (p = 0.742), indicating no significant deviation from perfect fit. The calculated Brier score was 0.082, further supporting the overall calibration of the model. Figure 4Bootstrap-corrected calibration curve of the final 5-variable clinical model for identifying left atrial enlargement. The X-axis represents the risk of LAE predicted by the visual nomogram, and the Y-axis represents the actual observed rate of LAE. The dashed diagonal line (45-degree ideal reference line, labeled “Ideal”) represents perfect prediction, on which predicted probabilities are completely consistent with the true observed outcomes. The dotted curve (“Apparent”) shows the uncalibrated raw calibration curve of the nomogram without bootstrap correction. The solid line (“Bias-corrected”) represents the actual performance of the model corrected via internal validation with 1,000 bootstrap resamples. The pale gray solid band (“C.L.”) stands for the confidence limits of the bias-corrected calibration curve. The close alignment between the calibration curve and the reference line indicates good calibration, with a mean absolute error (MAE) of 0.017, demonstrating close agreement between predicted and observed probabilities.Graph: predicted vs actual probability of left atrial enlargement. Bootstrap-corrected calibration curve of the final 5-variable clinical model for identifying left atrial enlargement. The X-axis represents the risk of LAE predicted by the visual nomogram, and the Y-axis represents the actual observed rate of LAE. The dashed diagonal line (45-degree ideal reference line, labeled “Ideal”) represents perfect prediction, on which predicted probabilities are completely consistent with the true observed outcomes. The dotted curve (“Apparent”) shows the uncalibrated raw calibration curve of the nomogram without bootstrap correction. The solid line (“Bias-corrected”) represents the actual performance of the model corrected via internal validation with 1,000 bootstrap resamples. The pale gray solid band (“C.L.”) stands for the confidence limits of the bias-corrected calibration curve. The close alignment between the calibration curve and the reference line indicates good calibration, with a mean absolute error (MAE) of 0.017, demonstrating close agreement between predicted and observed probabilities. Finally, decision curve analysis (DCA) was performed to evaluate the clinical utility and net benefit of the adjusted 5‑variable model (Figure 5). The DCA curve showed that, across a wide range of practical threshold probabilities, using the nomogram to predict LAE provided a significantly higher net benefit than either the treat‑all or treat‑none strategy. This finding indicated the potential clinical usefulness of the model for risk stratification (Figure 5). Figure 5Decision curve analysis (DCA) of the 5-variable clinical model for identifying LAE. The X-axis represents the threshold probability, and the Y-axis represents the net benefit. The pale green solid horizontal line represents the “treat-none” strategy (assuming no patients experience the outcome, resulting in zero net benefit). The pale red solid slanted line represents the “treat-all” strategy (assuming all patients are screened/treated). The light blue solid curve represents the net benefit achieved by applying the adjusted 5-variable model combining Age, hypertension duration, AF, hypertension stage, and CHD. Across a wide range of threshold probabilities, the model’s curve remains substantially above both the “treat-all” and “treat-none” reference lines, demonstrated greater net benefit than the treat-all and treat-none strategies.A line graph showing net benefit versus threshold probability for treat all, treat none and 5-variable model. Decision curve analysis (DCA) of the 5-variable clinical model for identifying LAE. The X-axis represents the threshold probability, and the Y-axis represents the net benefit. The pale green solid horizontal line represents the “treat-none” strategy (assuming no patients experience the outcome, resulting in zero net benefit). The pale red solid slanted line represents the “treat-all” strategy (assuming all patients are screened/treated). The light blue solid curve represents the net benefit achieved by applying the adjusted 5-variable model combining Age, hypertension duration, AF, hypertension stage, and CHD. Across a wide range of threshold probabilities, the model’s curve remains substantially above both the “treat-all” and “treat-none” reference lines, demonstrated greater net benefit than the treat-all and treat-none strategies. Discussion In this study, we developed and internally validated a diagnostic nomogram incorporating five routinely available clinical variables (age, hypertension duration, hypertension stage, AF, and CHD) to estimate the probability of LAE in patients with essential hypertension. The model exhibited good discriminative performance, with an apparent AUC of 0.937, suggesting it may serve as a supplementary tool for preliminary LAE risk stratification among patients with essential hypertension. The optimism-corrected AUC of 0.920 after bootstrap internal validation further suggested that the model retained relatively stable discrimination despite the limited number of LAE events. Our multivariable analysis identified advanced age, increased hypertension duration, and atrial fibrillation as independent factors associated with LAE. These findings are biologically plausible and consistent with previous evidence regarding atrial remodeling. Advanced age may contribute to atrial remodeling through age-related myocardial fibrosis, impaired ventricular relaxation, and progressive diastolic dysfunction. When combined with hypertension-related arterial stiffness and increased ventricular filling pressure, these processes may contribute to chronic elevation of left atrial wall stress and subsequent atrial enlargement.15,16 Notably, hypertension duration was independently associated with LAE (OR = 2.00 per grade increase, p = 0.003), which corroborates prior longitudinal evidence that cumulative exposure to elevated blood pressure exerts a progressive haemodynamic burden on the left ventricle, eventually leading to diastolic dysfunction and left atrial pressure overload.17 From a mechanistic standpoint, the duration of hypertension likely represents the cumulative effect of mechanical stretch and neurohumoral activation on the atrial myocardium, which may contribute to extracellular matrix remodeling and progressive structural enlargement over time. An intriguing observation regarding hypertension stage was that its Stage 2 category appeared to confer a lower risk score than the Stage 1 category, although this variable did not reach statistical significance (p = 0.101). This unexpected pattern may reflect differences in disease characteristics, treatment exposure, or residual confounding, which could not be fully assessed in this retrospective cross-sectional study. Alternatively, hypertension duration may better capture the cumulative haemodynamic burden associated with LAE than a single cross-sectional blood pressure category. Our findings also corroborate the well-recognised bidirectional interplay between AF and atrial structural remodeling, consistent with the “AF begets AF” paradigm.18,19 Given the cross-sectional design, AF should be interpreted as a concurrent marker of atrial remodeling rather than a causal antecedent of LAE. The strong association between AF and LAE likely contributes to the model’s discrimination performance. Although hypertension stage and coronary heart disease did not reach statistical significance in the multivariable model, both variables were retained in the final nomogram because of their established clinical relevance and potential contribution to risk stratification. Variable inclusion in prediction models should not rely solely on individual P values, as clinically meaningful variables may provide incremental information and improve model interpretability even when their independent associations do not achieve conventional statistical significance. Hypertension stage may serve as a surrogate indicator of cumulative blood pressure burden and hypertension-mediated target-organ damage, whereas coronary heart disease reflects the broader cardiovascular disease burden associated with adverse cardiac remodeling. Therefore, retaining these prespecified variables aimed to balance statistical performance with clinical applicability and interpretability of the nomogram.20 A key strength of our nomogram lies in its derivation from routine, readily obtainable clinical parameters, yielding satisfactory discrimination without requiring echocardiographic parameters as input variables. This feature provides a practical framework for preliminary risk stratification using routinely available clinical information. While electrocardiography or chest radiography may offer indirect clues, they are limited in detecting subtle structural remodeling. Importantly, our nomogram is not intended to replace established diagnostic approaches, including electrocardiography, chest radiography, or echocardiography. Instead, it serves as a complementary screening instrument to flag individuals with a higher probability of LAE, prompting more definitive echocardiographic work‑up and comprehensive clinical assessment. Several methodological considerations should be taken into account when interpreting the present findings. The retrospective, single‑centre design and relatively small sample (n = 251), together with a low event count (26 LAE cases), may introduce selection bias and increase the risk of model overfitting. Although internal validation was performed using bootstrap resampling, the stability and generalisability of the nomogram require confirmation in larger, independent, preferably multicentre populations. Therefore, the current model should be considered a preliminary risk stratification approach requiring further external validation before broader clinical application. The definition of LAE itself warrants caution, as it was based on the left atrial anteroposterior diameter rather than the current guideline‑recommended volumetric measure (LAVI), a choice dictated by the availability of historical electronic data. Thus, the present model should be interpreted as a risk stratification approach for LAE defined by routine linear echocardiographic measurements rather than a substitute for comprehensive volumetric assessment. Future prospective studies incorporating LAVI and advanced functional parameters such as left atrial strain may further refine this risk stratification framework. Another methodological point is that echocardiographic parameters, including LVDD and LVH, were not included as candidate predictors in the present model. Although both LVDD and LVH are pathophysiologically linked to left atrial dilation, excluding these echocardiographic measures was a deliberate design choice to preserve the model’s utility as an easily accessible screening approach based on demographic characteristics and clinical history data. Future external validation in larger and independent populations will be necessary before broader application of this nomogram.6,16 Conclusions We developed and internally validated a diagnostic nomogram for estimating the probability of concurrent left atrial enlargement (LAE) in patients with essential hypertension. The model incorporates five routinely available clinical parameters—age, hypertension duration, atrial fibrillation, hypertension stage, and coronary heart disease—and may assist clinicians with preliminary risk stratification, particularly in settings where echocardiographic assessment is not immediately available. This framework may assist clinicians, particularly in primary care settings, in identifying individuals with a higher likelihood of LAE. Nevertheless, given the single‑centre, retrospective, cross‑sectional design and the lack of external validation, these findings should be interpreted with caution. Prospective, multicentre studies are warranted before the model can be recommended for broader clinical implementation.